Entity Details

Primary name EPHB4_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionP54760
EntryNameEPHB4_HUMAN
FullNameEphrin type-B receptor 4
TaxID9606
Evidenceevidence at protein level
Length987
SequenceStatuscomplete
DateCreated1996-10-01
DateModified2021-06-02

Ontological Relatives

GenesEPHB4

GO terms

Show/Hide Table
GOName
GO:0001525 angiogenesis
GO:0002042 cell migration involved in sprouting angiogenesis
GO:0003007 heart morphogenesis
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0005003 ephrin receptor activity
GO:0005005 transmembrane-ephrin receptor activity
GO:0005524 ATP binding
GO:0005576 extracellular region
GO:0005829 cytosol
GO:0005886 plasma membrane
GO:0005887 integral component of plasma membrane
GO:0007155 cell adhesion
GO:0007169 transmembrane receptor protein tyrosine kinase signaling pathway
GO:0007275 multicellular organism development
GO:0007411 axon guidance
GO:0033674 positive regulation of kinase activity
GO:0043005 neuron projection
GO:0043235 receptor complex
GO:0046777 protein autophosphorylation
GO:0048013 ephrin receptor signaling pathway
GO:0070062 extracellular exosome

Subcellular Location

Show/Hide Table
Subcellular Location
Cell membrane

Domains

Show/Hide Table
DomainNameCategoryType
IPR000719 Protein kinase domainDomainDomain
IPR001090 Ephrin receptor ligand binding domainDomainDomain
IPR001245 Serine-threonine/tyrosine-protein kinase, catalytic domainDomainDomain
IPR001426 Tyrosine-protein kinase, receptor class V, conserved siteSiteConserved site
IPR001660 Sterile alpha motif domainDomainDomain
IPR003961 Fibronectin type IIIDomainDomain
IPR008266 Tyrosine-protein kinase, active siteSiteActive site
IPR008979 Galactose-binding-like domain superfamilyFamilyHomologous superfamily
IPR009030 Growth factor receptor cysteine-rich domain superfamilyFamilyHomologous superfamily
IPR011009 Protein kinase-like domain superfamilyFamilyHomologous superfamily
IPR011641 Tyrosine-protein kinase ephrin type A/B receptor-likeDomainDomain
IPR013761 Sterile alpha motif/pointed domain superfamilyFamilyHomologous superfamily
IPR013783 Immunoglobulin-like foldFamilyHomologous superfamily
IPR016257 Ephrin receptor type-A /type-BFamilyFamily
IPR017441 Protein kinase, ATP binding siteSiteBinding site
IPR020635 Tyrosine-protein kinase, catalytic domainDomainDomain
IPR027936 Ephrin receptor, transmembrane domainDomainDomain
IPR034290 Ephrin type-B receptor 4, ligand binding domainDomainDomain
IPR036116 Fibronectin type III superfamilyFamilyHomologous superfamily
IPR037636 EPH-B4, SAM domainDomainDomain

Diseases

Show/Hide Table
Disease IDSourceNameDescription
617300 OMIMLymphatic malformation 7 (LMPHM7)A form of primary lymphedema, a disease characterized by swelling of body parts due to developmental anomalies and functional defects of the lymphatic system. Patients with lymphedema may suffer from recurrent local infections. LMPHM7 is an autosomal dominant form with variable expressivity. Some individuals present with severe non-immune hydrops fetalis, which may cause perinatal demise or fully resolve after the neonatal period. Others present with no edema and have milder clinical features, such as atrial septal defect or varicose veins as adults. The disease is caused by variants affecting the gene represented in this entry.
618196 OMIMCapillary malformation-arteriovenous malformation 2 (CMAVM2)An autosomal dominant disorder characterized by multiple, round to oval or more irregularly shaped macules that are pinkish red in color and are randomly distributed across the body. These capillary malformations are associated with either arteriovenous malformation, arteriovenous fistula, or Parkes Weber syndrome. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB01254 DasatinibDrugbanksmall molecule
DB07249 N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amineDrugbanksmall molecule
DB07250 N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINEDrugbanksmall molecule
DB07251 N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINEDrugbanksmall molecule
DB07252 3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamideDrugbanksmall molecule
DB07253 N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamineDrugbanksmall molecule
DB07254 N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDEDrugbanksmall molecule
DB07255 N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINEDrugbanksmall molecule
DB07256 3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDEDrugbanksmall molecule
DB11973 TesevatinibDrugbanksmall molecule
DB12010 FostamatinibDrugbanksmall molecule